EXPLORING THE THERAPEUTIC POTENTIAL OF XANTHINE OXIDASE INHIBITORS IN CORONARY ARTERY DISEASE - allopurinol in CAD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003081-42-GB

Enrollment

124

Registered

2005-07-25

Start date

2005-10-06

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ishaemic heart disease

Interventions

Product Name: Allopurinol Product Code: PL 0142/0147 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Stable angina pectoris with no heart failure 2) Acute MI Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1 and 2) Renal failure. Creatinine > 190mM/l Contraindication to allopurinol (as per BNF)

Design outcomes

Primary

Measure	Time frame
Main Objective: 1) To assess if allopurinol improves endothelial function in angina patients. 2) To assess if allopurinol improves post MI LV remodelling in post MI patients;Secondary Objective: ;Primary end point(s): 1) Change in endothelial function as assessed by strain gauge plethysmography and infusion of vasoactive substances and also USS assessment of FMD, compared to placebo 2) Change in LV remodelling assessed by MRI compared to placebo	—

Measure

Time frame

Main Objective: 1) To assess if allopurinol improves endothelial function in angina patients. 2) To assess if allopurinol improves post MI LV remodelling in post MI patients;Secondary Objective: ;Primary end point(s): 1) Change in endothelial function as assessed by strain gauge plethysmography and infusion of vasoactive substances and also USS assessment of FMD, compared to placebo 2) Change in LV remodelling assessed by MRI compared to placebo

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026